Immune‐mediated hemolytic anemia (IMHA) causes severe anemia in dogs and is
associated with considerable morbidity and mortality. Treatment with various …

Background Treatment of dogs with primary immune‐mediated hemolytic anemia (IMHA) is
difficult and frequently unrewarding. Prognostic factors have been evaluated in a number of …

Immune-mediated hemolytic anemia is one of the most common manifestations of canine
immune-mediated disease, yet treatment regimens remain nonstandardized and, in some …

Background Outcome prediction in dogs with immune‐mediated hemolytic anemia (IMHA) is
challenging and few prognostic indicators have been consistently identified. Objectives An …

Objective To compare short‐term outcome and frequency of adverse events for dogs with
idiopathic immune‐mediated haemolytic anaemia treated with glucocorticoids and …

Background The dog is the most popular companion animal and is a valuable large animal
model for several human diseases. Canine immune-mediated hematological diseases …

Cytokine abnormalities have been described previously in dogs with varied immune
mediated and inflammatory conditions such as IMHA and sepsis. The purpose of this study …

Background Current reports about the use of splenectomy for the management of immune‐
mediated hemolytic anemia (IMHA) or immune‐mediated thrombocytopenia (ITP) or both in …

Methods A randomised non‐blinded non‐inferiority trial was conducted to determine
whether treatment with an unfractionated regimen of oral prednisolone was inferior to a …

Immune-mediated hemolytic anemia (IMHA) is among the most common hematologic
disorders of dogs. Despite years of research, the disease continues to cause substantial …